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Abstract this group of SLE patients, but not related with di-
sease activity or damage. These findings suggest
that disease activity, cumulative damage and QoL
are independent outcome measures and should all
be used to assess the full impact of disease in SLE
patients.
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Purpose: To evaluate quality of life in Portuguese
patients with Systemic Lupus Erithematosus (SLE)
and its correlation with disease activity and cumu-
lative damage.
Methods: We included consecutive SLE patients,
fulfilling the 1997 ACR Classification Criteria for
SLE and followed at the Rheumatology Department
of the University Hospital of Coimbra, Portugal at
time of visit to the outpatient clinic. Quality of life
was evaluated using the patient self-assessment
questionnaire Medical Outcomes Survey Short
Form-36 (SF-36) (validated Portuguese version).
The consulting rheumatologist fulfilled the SLE as-
sociated indexes for cumulative damage (Systemic
Lupus International Collaborating Clinics- Dama-
ge Index: SLICC/ACR-DI) and disease activity
(Systemic Lupus Erythematosus Disease Activity
Index: SLEDAI2000). Correlation between SLED AI
and SLICC and SF-36 was tested with the Spearman
Coefficient. Significant level considered was 0.05.
Results: The study included 133 SLE patients
(90.2% female, mean age - 40.7 years, mean disea-
se duration - 8.7 years). Most patients presented
low disease activity (mean SLEDAI = 4.23) and limi-
ted cumulative damage (mean SLICC = 0.76). Des-
pite that, SF-36 mean scores were below 70% in all
eight domains of the index. Physical function do-
mains showed lower scores than mental function
domains. The QoL in this group of patients is sig-
nificantly impaired when compared with the refe-
rence Portuguese population (p<0.05 in all do-
mains). There was no correlation between clinical
activity or cumulative damage and quality of life.
Conclusion: QoL is significantly compromised in
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Introduction
Systemic Lupus Erythematosus (SLE) is a multi-
system rheumatic autoimmune disease, with a
chronic course characterized by alternate episodes
of remission and exacerbation that may involve al-
most any organ or system, with high variability
among patients and in the same patient over time.
Over the last decades, the advances in diagnosis
and management of SLE improved significantly the
survival of SLE patients, from an acute disease with
a high rate of short-term mortality in the 195O's to
a chronic condition with five year survival rates
now approaching 95%'" and 10-year survival rates
above 85%' ^ at least for those patients managed at
specialized centers. Consequently, outcome mea-
sures in SLE must go much beyond mortality data.
At present, optimal care for SLE patients aims to
provide a long-term health status as close to that of
the general population as possible. To guide qua-
lity clinical care there is a need to characterize and
monitor the full spectrum of SLE effects, including
disease activity (reversible), cumulative damage (ir-
reversible) and health-related quality of life. A com-
prehensive assessment should consider these dif-
ferent domains, as recommended^"^.
Disease activity outcome measures include an
evaluation of a variety of clinical and laboratorial
findings, related to intrinsic disease mechanism.
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and are potentially reversible with treatment. Cu-
niulative damage is irreversible, and could be due
to the disease, its treatment or both, or co-morbi-
dities. However these outcomes, based essentially
in physical and laboratorial findings, do not di-
rectly capture the psychological and social impact
of the disease or its treatment in patient's QoL. As
a chronic disease, SLE has, apart from physical im-
pact in terms of disease activity and irreversible
and cumulative organ damage, a wide range of im-
pacts in emotional, psychological and social as-
pects of patient's life^
Health Related Quality of Life (HRQoL) has been
defined as a multi-domain concept that represents
the patient's overall perception of the impact of an
illness and its treatments" and the degree to which
persons perceive themselves able to function
physically, emotionally and socially. Assessing the
QoL is thus an important measure to appraise how
niuch the disease and its treatment is affecting an
individual'" and his or her physical, mental and so-
cial domains of life.
There are several instruments validated to eva-
luate QoL in healthy and disease populations. The
most commonly used worldwide is the Medical
Outcomes Short Form Survey 36 (SF-36). Several
studies in general healthy populations demonstra-
ted that normal values vary greatly between diffe-
rent countries""'^
Previous studies in other countries showed a
significant compromise of QoL in SLE patients,
with lower QoL when compared with healthy con-
trols or population norms"''^ Mean QoL of SLE
patients was found to be worst than in patients
with hypertension, myocardial infarction or diabe-
tes^". Studies comparing SLE with RA show a hig-
her impact among RA patients in the physical com-
ponents but with similar results for mental com-
ponents'^'^'. There are no previous studies charac-
terising QoL in a representative SLE population in
Portugal.
The relationship between QoL with disease ac-
tivity and cumulative damage has been researched
in previous studies with confiicting results'"' "'•22-25
It is also possible that the potential contribution
of disease activity and cumulative damage to QoL
varies in SLE populations in different countries.
We hypothesise that the QoL of SLE patients in Por-
tugal correlates with disease activity and damage.
Alternatively QoL may depend upon[the patient's
overall perception of the impact of the illness and
its treatments, more related to psychosocial and
cultural context than to objective disease outcome
measures.
The objectives of this study were: 1) to charac-
terise QoL in a representative SLE population in
Portugal; 2) to evaluate correlation of QoL in this




One hundred and thirty three consecutive patients
attending the Lupus Clinic of the Rheumatology
Department at Coimbra University Hospital were
enrolled in this cross sectional study, between 2006
and 2008. All patients met > 4 of the American Col-
lege of Rheumatology (ACR) Criteria for Classifica-
tion of SLE l^ Patients unable to understand or to
answer the self-questionnaire were excluded.
Study Evaluation
Study evaluation was cross-sectional and data col-
lected at time of programmed visit to the Outpa-
tient Clinic. Disease activity and cumulative da-
mage measures were evaluated by the physician
and the patient fulfilled the self-questionnaire of
QoL at time of inclusion.
Assessment of QoL
QoL was assessed with the Portuguese validated
version of the self-administered SF-36 question-
naire"' 2^  This is a general, non disease-specific,
validated instrument for QoL assessment of gene-
ral population as well as patients with chronic
illnesses as SLE. This instrument consists of 36
items covering eight domains: Physical Function
(PF), Physical role (PR), Bodily pain (BP), Vitality
(V), Ceneral Health (GH), Emotional Role (ER),
Mental Health (MH) and Social Functioning (SF).
The global score and the ones for each domain ran-
ges from 0 to 100 with higher scores indicating bet-
t QL^s
Measure of Disease activity:
Clinical activity of SLE was assessed using SLEDAI
2000™. It is a physician-rated, valid and reliable in-
dex of lupus activity that reports on 24 descriptors
with pre-assigned severity weights. The total SLE-
DAI score can range from 0 (no activity) to 105 (ma-
ximum activity).
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Measure of Cumulative Damage
Clinical damage due to SLE was assessed using The
Systemic Lupus International Collaborating Cli-
nic/ American College of Rheumatology Damage
Index (SLICC/ACR DI)''. Damage means irreversi-
ble impairment due to SLE or its treatment and is
usually defined as a clinical feature that has to be
continuously present for at least six months to sco-
re. The SLICC/ACR DI reports on 12 organs or sys-
tems which are ocular (ranges of score 0-2), neu-
ropsychiatrie (0-6), renal (0-3), pulmonary (0-5),
cardiovascular (0-6), peripheral vascular (0-5), gas-
trointestinal (0-6), musculoskeletal (0-6), derma-
tological (0-3), gonadal (0-1), diabetes (0-1) and
malignancy (0-2).
Statistical Analysis
All statistical analysis was performed by SPSS® ver-
sion 15.0. Categorical variables were presented as
percentage and continuous variables were presen-
ted as means and standard deviation (SD).
The normality for each variable was assessed
using Shapiro WilkTest. The Spearman rank corre-
lation test was applied to correlate disease activity
and damage with QoL in SLE patients. Comparison
of SF-36 scores for each domain between SLE pa-
tients and previously available representative re-
sults for the general Portuguese populations^ were
performed using a one-sample test.
A statistical significance was considered when
p<0,05.
Results
133 patients comprised the study population, with
90.2 % (n=120) women, mean age of 40.69± 14.02
years and mean disease duration of 8.69 + 7.13
years.
The mean disease activity, as assessed by SLE-
DAI in these patients is low (4.23± 4.27; range from
0 to 33). The majority of the patients (70.4%) are in
remission or mildly active, with a SLEDAI score
lower than six and only 4.3% of patients presented
high disease activity with a score of 10 or higher
(Table I).
The cumulative damage is low, with a mean of
score of 0.76 (0.76± 1.09, range from 0 to 5). The ma-
jority of patients (54.6%) do not present any irre-
versible damage due to SLE or its treatment
(SLICC/DI=O)(TableI).
QoL assessed by SE-36 is low in this group of
SLE patients. Mean scores are lower than 70% in all
domains, with lower scores in the General Health
domain (39,04%). The mean scores are lower for
the four domains of the physical component than
for the domains of mental component (Table I).
Due the non-normality of data (Shapiro Wilk
Test, p<0,05), Spearman rank correlation was used
to test correlations between QoL and disease acti-
vity (SLEDAI), cumulative damage (SLICC), disea-
se duration and age. Except for Physical Function
and Physical Role, all domains varied inversely
with SLEDAI, although none achieved statistical
significance.
No correlation is observed between cumulative
damage assessed by SLICC/DI and SE-36 domains
(Table II).
No correlation exists also between disease du-
ration and any scores of SE-36. There is a weak ne-
gative correlation between age and all domains in-
cluded in SF-36 (r varies between -0,2 to -0,4,
p<0,01 for all domains).
When comparing the SE-36 in SLE patients, with
results previously published from a large sample
representative of the general Portuguese popula-
tions^ the scores are statistically lower in the SLE
population. Despite being statistically significantly
lower. Mental Health was the domain with scores
closer to those observed in the general Portugue-
se population (59.22 vs 64.04%; p=0.03). All the
other domains present a higher mean difference
(between 8 and 23%; p<0.001 for all of them). The
difference to the Portuguese Population is higher
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Table 11. Correlation of Quality of Life (MOS SF-36) and Disease




















































QoL is becoming an important focus on clinical
research during the last years, mainly in chronic di-
seases as SLE. Studies have been conducted in
other countries but to our knowledge no published
Studies exist in Portugal, regarding SLE.
In our study, QoL in this sample of SLE patients,
assessed by SF-36, is low. The major impact is
observed in the domains of the physical compo-
nent. When compared with the reference values
from a large Portuguese sample•^ ^ all scores are sig-
nificantly lower.
Patients present a mean low disease activity,
with the majority of the patients in remission or
inactive disease. The damage is also low in this co-
hort of patients, with more than half of the patients
without any organ damage due the disease or its
treatment. Wedidnotfinda statistically correlation
between QoL and disease activity or damage in this
group of patients.
Our results are consistent with other published
studies. All the studies conducted show lower qua-
lity of life in SLE patients when compared with
what is expected for the reference general popula-
tion'""'" or when compared with healthy con-
The absence of correlation between disease ac-
tivity and QoL found in our study is also reported
in other studies. Most studies using SLEDAI''•2''36.37
to assess disease activity showed no correlation
with QoL. However, other studies reported an as-
sociation. Two studies, from South Africa and USA,
report a weak negative correlation of SLEDAI with
physical component but not with mental compo-
nents of SF-36'«2. One study from China found a
negative association between disease activity and
both components of SF-36^^ another study with
Mexican women reported a negative weak cor-
relation between SLEDAI and some domains of
SF-362^ When BILAG is used as a measure of disea-
se activity, a weak correlation is reported in 3 stu-
diegi4,38,39 Interestingly, when SLAM is used, a ne-
gative correlation with QoL is shown in most stu-
cliesi8.24,36 jjj t^o of them"'•3^ both SLAM and SLE-
DAI were used and a correlation of QoL with SLAM
was found but not with SLEDAI. This discrepancy
could be due to a higher sensitivity of SLAM to pa-
tient's SLE related subjective complaints that are
not scored in the SLEDAI or BILAG.
Similar to ours, some studies from Canada,
Syngapore and Brazil, report no association betwe-
en damage and QoL '^'^ «"»" other studies found
that damage was correlated with QOL''''^"'^^:'^ hut
this correlation was usually weak and only for
physical domains of SF-36.
A recent comprehensive review of literature of
QoL in SLE patients shows the discrepancy betwe-
en studies in this field and the tendency of no cor-
relation vkdth disease activity or damage".
Important caveats should be referred in our
study. This is a cross sectional study, without a
comparison group. We made an indirect compari-
son, using data reporting SF-36 scores from a re-
presentative sample from the Portuguese general
population. This carries some limitations. Socio-
demographic and clinical factors, known as poten-
tial predictors of QoL, could not be adjusted for
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this comparison, such as gender, age, level of edu-
cation, type of work, income, labour activity status,
social support, residence area, depression, anxiety
or fibromyalgia. For example, our SLE population
included more women (90.2% vs 58.1%) and stu-
dies of QoL show that women tend to have lower
scores. This study was conducted in one single cen-
tre in the central region of the country. The gene-
ralizahility of these results should be made care-
fully. However, according with previous publicati-
ons, our cohort is similar with other Portuguese
Cohorts•'•'••'^  and, in our understanding, be repre-
sentative of Portuguese SLE Patients.
Future studies, comparing with healthy controls
and adjusting for these variables, are necessary to
confirm and validate our results and better charac-
terize SLE impact on QoL.
In conclusion, this study characterised QoL in a
large Portuguese SLE population. This provides
previously unavailable data for SLE patients in this
country. The indirect comparison with the Portu-
guese general population suggests a significant im-
pact of SLE in the patient's QoL. The low QoL pre-
sented by these patients could not be explained by
SLE disease activity and cumulative damage. This
corroborates similar results from most studies in
other countries.
These results support the concept of QoL as an
independent outcome measure that should be in-
corporated in the quality care management of SLE
patients. Assessing QoL is thus an important mea-
sure to appraise how much the disease process and
its treatment is affecting an individual, to identify
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